The head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients

Gómez, Ruth Gabriela Herrera; Mezquita, Laura; Auclin, Édouard; Heraudet, Luc; Plana, Maria; Salas, Sébastien; Cristina, Valérie; Castaño, Almudena García; Arrazubi, Virginia; Grau, Juan J.; Saleh, Khalil; Cirauqui, Beatriz; Nin, R. Mesía; Even, Caroline; Taberna, M.; Daste, Amaury; Peters, Solange; Besse, Benjamin; Baste-Rotllan, N.

doi:10.1093/annonc/mdz252.051

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reviewing the remaining 39 articles via the full-text view, 27 full-text articles were excluded due to lack of intended outcomes (OS, PFS), HR with 95% CI or repeatedly published studies. Finally, 12 studies published between 2018 and 2020 were included in this analysis (11)(12)(13)(14)(19)(20)(21)(22)(23)(24)(25)(26).…”

Section: Retrieval Results and Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis

Liu

Yang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. However, its predictive value for other types of cancer remained unclear. This meta-analysis aimed to evaluate the association between pretreatment LIPI score and therapeutic outcomes in cancer patients treated with ICIs.MethodsWe searched PubMed, Cochrane Library literature databases and EMBASE for abstracts and full-text articles published from the inception of the database until 16th, Nov 2020. Meta-analyses were performed separately for progression-free survival (PFS) and overall survival (OS) by using the random-effects model.ResultsA total of 12 studies involving 4883 patients receiving ICIs treatment were identified for the primary analysis. The pooled results implied that compared with good LIPI score groups, patients with poor or intermediate LIPI score were significantly associated with worse OS (HR=3.33, 95%CI 2.64-4.21, P < 0.001, I2 = 64.2%; HR=1.71, 95%CI 1.43-2.04, P < 0.001, I2 = 43.6%, respectively) and PFS (HR=2.73,95%CI 2.00-3.73, P < 0.001, I2 = 78.2%; HR=1.43, 95%CI 1.28-1.61, P < 0.001, I2 = 16.3%, respectively). Also, for 1873 patients receiving chemotherapy, a poor LIPI score was significantly associated with worse OS (HR=2.30, 95%CI 1.73-3.07, P < 0.001; I2 = 56.2%) and PFS (HR=1.92,95%CI 1.69-2.17; P < 0.001; I2 = 0.0%) compared with good LIPI score groups.ConclusionsA good LIPI score was significantly correlated with improved OS and PFS in cancer patients receiving ICIs or chemotherapy, regardless of the types of cancer.

show abstract

Section: Retrieval Results and Study Characteristicsmentioning

confidence: 99%

“…Current evidence proved that the LIPI score could be used to identify cancer patients who benefit from ICIs treatment in multiple cancers ( 11 , 12 ). Meanwhile, contradictory results have also been published ( 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis

Liu

Yang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Compared to patients in the good prognostic group, those in the intermediate and poor prognostic groups had significantly shorter median PFS and OS when treated with immunotherapy, but no difference was observed among patients receiving chemotherapy [94]. Subsequent studies have confirmed the reliability of the LIPI score in stratifying the prognosis of patients treated with immune-checkpoint inhibitors in several other cancer types, including melanoma, renal cancer, small cell lung carcinoma, head and neck squamous cell carcinoma, urothelial cancer, and triple-negative breast cancer [98][99][100][101][102][103][104][105].…”

Section: Prognostic Value Under Immunotherapymentioning

confidence: 97%

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Mosca,

Nigro,

Pagani

et al. 2023

Biomolecules

View full text Add to dashboard Cite

In the era of immunotherapy, identifying biomarkers of immune system activation has become a high-priority challenge. The blood neutrophil-to-lymphocyte ratio (NLR) has been largely investigated as a biomarker in several cancer types. NLR values have been shown to mirror the tumor-induced inflammatory status and have been demonstrated to be a reliable prognostic tool across stages of disease and therapeutic approaches. When integrated with other biomarkers of response to immunotherapy, such as PD-L1, tumor mutational burden, and tumor-associated immune cells, the NLR may allow to further stratify patients with different likelihoods of deriving a significant clinical benefit. However, despite its accessibility, low cost, and easy interpretation, the NLR is still poorly used as a prognostic tool in daily clinical practice. In this review, we analyze the role of the NLR in defining the relationship between cancer and the immune system, its usefulness in daily clinical practice, and its relationship with other established or emerging biomarkers of immunotherapy outcomes.

show abstract

“…The lung immune prognostic index (LIPI), a score incorporating the derived-NLR (dNLR) and serum LDH levels, demonstrated its prognostic value rst in non-small cell lung cancer (NSCLC) [7]. Subsequent studies showed its association with disease progression and mortality risk in other tumor types, such as genito-urinary [8,9], breast [10], melanoma [9], and head and neck cancers [11], suggesting its agnostic applicability. No studies explored the short-term prognostic validity of the LIPI score.…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy

De Giglio,

Leonetti,

Comito

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Immune checkpoint inhibitors (ICIs) are standard treatments for advanced solid cancers. Resistance to ICIs, both primary and secondary, poses challenges, with early mortality (EM) within 30–90 days indicating a lack of benefit. Prognostic factors for EM, including the Lung Immune Prognostic Index (LIPI), remain underexplored. Methods: We performed a retrospective, observational study including patients affected by advanced solid tumors, treated with ICI as single-agent or combined with other agents. Logistic regression models identified factors associated with EM and 90-day progression risks. A nomogram for predicting 90-day mortality was built and validated within an external cohort . Results: 637 patients received ICIs (single-agent or in combination with other drugs) for advanced solid tumors. Most patients were male (61.9%), with NSCLC as the prevalent tumor (61.8%). Within the cohort, 21.3% died within 90 days, 8.4% died within 30 days, and 34.5% experienced early progression. Factors independently associated with 90-day mortality included ECOG PS 2 and a high/intermediate LIPI score. For 30-day mortality, lung metastasis and a high/intermediate LIPI score were independent risk factors. Regarding early progression, high/intermediate LIPI score was independently associated. A predictive nomogram for 90-day mortality combining LIPI and ECOG PS achieved an AUC of 0.76 (95% CI, 0.71–0.81). The discrimination ability of the nomogram was confirmed in the external validation cohort (n = 255) (AUC 0.72,95% CI, 0.64–0.80). Conclusion: LIPI and ECOG PS independently were able to estimate 90-day mortality, with LIPI also demonstrating prognostic validity for 30-day mortality and early progression.

show abstract

The head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients

Cited by 5 publications

References 0 publications

The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis

The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy

Contact Info

Product

Resources

About